Posted by Michael Wonder on 06 Sep 2023
X4 Pharmaceuticals announces submission of new drug application to US FDA for mavorixafor in WHIM syndrome
5 September 2023 - Submission supported by positive results from global, pivotal 4WHIM Phase 3 clinical trial.
X4 Pharmaceuticals today announced the submission of a new drug application to the US FDA for the approval of once-daily, oral mavorixafor to treat individuals aged 12 and older with WHIM (Warts, Hypogammaglobulinemia, Infections, and Myelokathexis) syndrome, a rare, primary immunodeficiency.
